Jean E Abraham

List of Publications by Year
in descending order

22 papers	1,437 citations	516710 16 h-index	677142 22 g-index
22 all docs	22 docs citations	22 times ranked	3309 citing authors

#	Article	IF	Citations
1	Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncology, The, 2022, 23, 149-160.	10.7	148
2	Multi-omic machine learning predictor of breast cancer therapy response. Nature, 2022, 601, 623-629.	27.8	187
3	NRG1 fusions in breast cancer. Breast Cancer Research, 2021, 23, 3.	5.0	18
4	Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients. Cancer Research, 2021, 81, 6004-6017.	0.9	25
5	Fbxl17 is rearranged in breast cancer and loss of its activity leads to increased global O-GlcNAcylation. Cellular and Molecular Life Sciences, 2020, 77, 2605-2620.	5.4	10
6	Hyperpolarized ^{13}C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer. Radiology Imaging Cancer, 2020, 2, e200017.	1.6	40
7	ctDNA monitoring using patient-specific sequencing and integration of variant reads. Science Translational Medicine, 2020, 12, .	12.4	116
8	Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 2020, 24, 1-190.	2.8	11
9	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet, The, 2019, 393, 2599-2612.	13.7	225
10	Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2017, 18, 755-769.	10.7	18
11	A genomic approach to therapeutic target validation identifies a glucose-lowering *GLP1R* variant protective for coronary heart disease. Science Translational Medicine, 2016, 8, 341ra76.	12.4	100
12	Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 2016, 18, 21.	5.0	66
13	The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study. PLoS ONE, 2016, 11, e0158984.	2.5	15
14	A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 2015, 13, 306.	5.5	26
15	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56
16	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Response. Clinical Cancer Research, 2015, 21, 3094-3094.	7.0	1
17	A Bayesian adaptive design for biomarker trials with linked treatments. British Journal of Cancer, 2015, 113, 699-705.	6.4	26
18	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel. Clinical Cancer Research, 2014, 20, 2466-2475.	7.0	91

#	Article	IF	Citations
19	Saliva samples are a viable alternative to blood samples as a source of DNA for high throughput genotyping. BMC Medical Genomics, 2012, 5, 19.	1.5	120
20	CYP2D6 Gene Variants and Their Association with Breast Cancer Susceptibility. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1255-1258.	2.5	11
21	CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Research, 2010, 12, R64.	5.0	76
22	Common Polymorphisms in the Prostaglandin Pathway Genes and Their Association with Breast Cancer Susceptibility and Survival. Clinical Cancer Research, 2009, 15, 2181-2191.	7.0	51